Oncolytics Biotech Inc ONCY

Might JNJ bad news be good news for ONCY re: JNJ interest?

[itntdf]

Johnson & Johnson JNJ announced that it is stopping a phase III study called MACiTEPH, evaluating its pulmonary arterial hypertension (PAH) drug, macitentan (75 mg) in patients with chronic thromboembolic pulmonary hypertension (CTEPH).

 

CTEPH is a rare form of pulmonary hypertension that occurs when there is abnormally high pressure in the lungs’ small blood vessels.

 

The decision to end the CTEPH study, due to futility, was made at the recommendation of the study’s independent data monitoring committee following a pre-planned interim analysis.

[Noteable]

How does a chronic hypertension drug have any relevance to ONCY 's oncology platform drug in pelareorep?  Aren't you stretching again?

[itntdf]

must have missed where you thought i was stretching the first time. sorry you may have missed my instant comment to which you felt necessary to snark, but it started out with the word "MIGHT". seems to me if JNJ feels the pressure about losing drugs, whether it be through the patent cliff or a failure of a P3 trial, they might want to look at other places to take up some slack. oncy

[Noteable]

Unless you missed it I asked how a blood pressure drug has any relevance to an oncology drug? Please explain if you can.

[Noteable]

And YES any Big Pharma who is losing in one area and whose focus has changed to a different therapeutic area such as oncology, would certainly be interested in ONCY'S pelareorep to fill out their oncology product pipeline. Excuse the snarkiness on both of our parts but I don't read minds. So if you don't explain yourself fully, don't explain the niceties of an informed exchange.

[Noteable]

So if you don't explain yourself fully ... don't expect the niceties of an informed exchange .

[itntdf]

grab you box of crayons, go back down to your room in your mother's basement, and draw yourself a picture.

[Noteable]

itntdf? ... crayons? basement? picture? LPC? Brad Thompson?  Are all these related to one another?

[Noteable]

You're right itntdf. I overlooked the word "might". So YES it "might" be influential in ONCY'S favor.

[Buckhenry]

Now now now.... youins be nice to unnoteable. He thinks everyone should bowe down and acknowledge his self proclaimed omnipotence. 

[Noteable]

At Johnson & Johnson our commitment to innovation has paved the way in oncology for more than 30 years. We work every day to get in front of cancer, convening the brightest minds to create, nurture and deliver new approaches to detect, intercept and one day cure this disease. Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based